ADMA Biologics Bilan de santé
Santé financière contrôle des critères 6/6
ADMA Biologics possède un total de capitaux propres de $231.9M et une dette totale de $101.3M, ce qui porte son ratio d'endettement à 43.7%. Son actif total et son passif total sont $390.6M et de $158.7M. L'EBIT de ADMA Biologics est $117.7M ce qui fait que son ratio de couverture des intérêts 7.8. Elle dispose de liquidités et de placements à court terme de $86.7M.
Informations clés
43.7%
Ratio d'endettement
US$101.33m
Dette
| Ratio de couverture des intérêts | 7.8x |
| Argent liquide | US$86.71m |
| Fonds propres | US$231.89m |
| Total du passif | US$158.73m |
| Total des actifs | US$390.62m |
Mises à jour récentes de la santé financière
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29Analyse de la situation financière
Passif à court terme: Les actifs à court terme de ADMA ( $318.2M ) dépassent ses passifs à court terme ( $44.9M ).
Passif à long terme: Les actifs à court terme de ADMA ( $318.2M ) dépassent ses passifs à long terme ( $113.8M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de ADMA ( 6.3% ) est considéré comme satisfaisant.
Réduire la dette: Le ratio d'endettement de ADMA a été réduit de 229.1% à 43.7% au cours des 5 dernières années.
Couverture de la dette: La dette de ADMA est bien couverte par le flux de trésorerie opérationnel ( 84.9% ).
Couverture des intérêts: Les paiements d'intérêts de ADMA sur sa dette sont bien couverts par l'EBIT ( 7.8 x couverture).